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Abstract
Objective: To compare oxandrolone (OX) or strength training with nutrition alone (NA) for AIDS
wasting.
Subjects: Fifty patients with AIDS; 47 completing the study.
Interventions: Randomization to (1) NA with placebo pills, (2) nutrition with 10 mg of OX
administered orally twice a day, or (3) nutrition with progressive resistance training (PRT) for 12
weeks.
Main Outcome Measures: Midthigh cross‐sectional muscle area (CSMA), physical functioning (PF),
costs, and cost‐effectiveness in dollars/quality‐adjusted life‐years ($/QALYs).
Results: The OX and PRT subjects had increases in CSMA (7.0% 6 2.5%, P = 0.01; 5.0% 6 2.0%, P =
0.04, respectively), although these increases did not differ significantly from the NA arm (NA: 1.0%
6 1.0%; OX vs. NA: P = 0.09; PRT vs. NA: P = 0.26). Only PRT caused significant improvements in PF
(mean 6 SE: 10.4 6 3.8 points on a 100‐point scale) and 7 measures of strength (P values: 0.04 to
,0.001). There were no overall differences between groups in PF change. Among patients with
impaired baseline PF, however, OX was significantly less effective than NA and PRT was
significantly better than NA. All treatments led to increases in protein intake and performance; NA
and PRT also increased caloric intake. The institutional costs per subject in this trial were $983 for
NA, $3772 for OX, and $3189 for PRT. At a community‐based level of intensity, the institutional
costs per QALY were $45,000 (range: $42,000–$64,000) for NA, $147,000 (range: $147,000–
$163,000) for OX, and $31,000 (range: $21,000–$44,000) for PRT.
Conclusions: OX and PRT induce similar improvements in body composition, but PRT improves
quality of life more than nutrition or OX, particularly among patients with impaired PF. PRT was the
most cost‐effective intervention, and OX was the least cost‐effective intervention.
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Introduction
Wasting has been a prominent feature of HIV infection since its emergence. In the earlier stages of
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the epidemic, it was associated with extremely high morbidity and mortality, and it has been an
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AIDS‐defining condition since 1993. More recently, despite the development of improved therapies
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for HIV infection and a dramatic reduction in mortality and wasting, weight loss continues to be a
5

problem among infected persons. It is still strongly related to the risk of disease progression and
6,7

death, even in the era of highly active antiretroviral therapy (HAART). Of course, wasting remains
a devastating problem in most of the world affected by AIDS, where such therapy is not readily
available.
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Clinical trials have studied strength training and anabolic medications for the treatment of AIDS
wasting. In the presence of hypogonadism, testosterone clearly improves weight and lean body
9–11

mass.

Even in HIV‐seropositive persons who are eugonadal, testosterone can improve weight
12,13
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and synthetic parenteral androgens also seem to be effective.
Most
and lean body mass
studies of the efficacy of the oral androgen, oxandrolone (OX), have been small, observational, or
remain unpublished.
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The only published randomized clinical trial of OX alone was conducted
20

early in the epidemic for persons with wasting and significant muscle weakness. In this group
with myopathy, weight increased with the use of OX but strength did not and there were no
measures of body composition. A dose of 20 mg daily has been used safely for AIDS wasting as
14,17,18

reported in 2 abstracts and 1 published report
and lies at the upper end of the approved doses
of this drug for the promotion of weight gain in other medical conditions. The single study
comparing 5 mg daily with 15 mg daily for AIDS wasting found weight gain and improved appetite
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and activity only at the higher dose. Strength training alone is also effective for restoring weight
and lean body mass in HIV wasting,
with androgens.

12,13,21

but there have been no direct comparisons of exercise

Although increased dietary intake is required for weight gain and nutrition intervention is
considered the standard of care in the treatment of AIDS wasting, there have been no good studies
evaluating their effects on body composition.
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Clinical trials of pharmacologic and exercise
14,20

interventions for AIDS wasting have only occasionally included dietary counseling

or reported
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Quality of life has also been neglected in this seriously ill population. To address
dietary intake.
these gaps in the scientific literature, we conducted a randomized clinical trial comparing OX or
progressive resistance training (PRT) with placebo in the setting of intensive nutrition intervention,
using midthigh cross‐sectional muscle area (CSMA) and self‐reported physical functioning (PF) as
the major outcomes.
Although other researchers have explored the high cost of other mainstay AIDS interventions, such
as HAART,
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there have been no cost analyses of treatments for wasting, a devastating

complication, particularly in developing countries with more limited resources. This article
includes an analysis of costs of all 3 interventions for the clinical trial as well as for an estimated
community‐adapted model (ECM) of treatment. The ECM includes 24 rather than 12 weeks of a
somewhat less resource‐intensive treatment regimen. This study also presents a cost‐effectiveness
analysis.

METHODS
Subjects
Fifty subjects with AIDS wasting were studied in the trial between March 1998 and January 2001 at
Tufts University/New England Medical Center in Boston. Subjects were HIV‐seropositive and met 1
or more of the following definitions of wasting: (1) documented unintentional weight loss of 10%
from premorbid weight, (2) documented unintentional weight loss of 5% in the previous 6 months,
2

or (3) body mass index (BMI) ,20 kg/m . The following were exclusions for participation: (1)
excessive vomiting or diarrhea; (2) fever; (3) AIDS‐defining complication within 4 weeks before
enrollment; (4) corticosteroid, estrogen, progesterone, androgen, anticoagulant, or growth
hormone use within the previous 3 months; (5) history of life‐threatening reaction to androgens;
(6) pregnancy; (7) cardiovascular disease, uncontrolled hypertension, hepatic or renal failure,
bleeding disorder, diabetes, breast or prostate cancer, or hypercalcemia; (8) milk allergy; (9)
current use of injected drugs; (10) participation in supervised exercise in the previous 4 weeks;
(11) physical incapability of exercising; (12) total serum testosterone level ,300 ng/mL in men
(unless receiving testosterone replacement); and (13) change in anti‐HIV medications within 30
days. All procedures were approved by the Human Investigation Review Committee at New
England Medical Center/Tufts University. Informed consent was obtained from participants in
accordance with good research practices.

Interventions
The subjects were randomized to 1 of 3 study interventions for 12 weeks: (1) intensive nutrition
intervention with placebo tablets (nutrition alone [NA] arm), (2) intensive nutrition intervention
with 20 mg of OX daily (OX arm), or (3) intensive nutrition intervention with PRT (PRT arm).
Subjects who were not randomized to the PRT arm spent an additional 30 to 60 minutes weekly
with study personnel to provide comparable levels of attention.

Nutrition Intervention
All participants attended weekly individual visits ranging from 30 to 60 minutes in length. Three‐
day food records were obtained at baseline, week 6, and week 12 to evaluate dietary intake; 24‐
hour dietary recalls were used if 3‐day food records were not feasible. Weekly 24‐hour dietary

recalls were also used to assess intake in the intervening weeks. Dietary recommendations were
based on body weight and included higher than maintenance recommendations to achieve weight
gain. The goal for total caloric intake was 40 to 50 kcal/kg/d, and the goal for protein intake was 1.6
g/kg/d. Although subjects were encouraged to meet these goals from a variety of food sources, we
also supplied and recommended intake of an oral liquid supplement twice daily. Mead Johnson
Nutritionals (Evansville, IN) provided Sustacal HN, later remarketed as Boost, each can of which
contained 237 mL, 240 kcal, 15 g of protein, and 3 g of fat. At weekly sessions, attention was paid to
basic nutrition concepts and overcoming individual barriers to good dietary intake, including
symptoms, medication schedules, lack of facilities, inadequate social support, and poor access to
food. A complete discussion of obstacles encountered and strategies used is published elsewhere.
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Drug Intervention
Study drug was provided by BTG Pharmaceuticals (Iselin, NJ) as 2.5‐mg OX tablets and matching
placebo tablets; participants took 4 tablets twice daily. At weekly visits, participants in the NA and
OX arms were asked about potential side effects, especially priapism and androgenization. Blood
was drawn at weeks 6 and 12 to monitor liver function.

Exercise Intervention
Strength training was performed in a thrice‐weekly, one‐on‐one, periodized program with a
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research technician, using well‐described procedures. After a warm‐up period, 5 exercises were
performed: leg press, chest press, knee extension, seated row, leg press, and modified abdominal
curl‐ups. The first 4 exercises were performed on Keiser pneumatic strength training machines
(Keiser Corporation, Fresno, CA), including 3 sets of 8 repetitions each. The workload was
progressively increased toward a goal intensity of 80% of the 1 repetition maximum (1RM) on each
machine. 1RMs were retested at sessions 13 and 25 to evaluate progress, and resistance on each
machine was adjusted accordingly. Bent‐knee abdominal curl‐ups were initially performed at 2 sets
of 10 repetitions each and were gradually increased in repetitions and, later, with a free weight
plate over the chest.

Strength, Power, and Performance Testing
28

Muscle strength was assessed by 1RM testing on 4 Keiser pneumatic strength training machines:
leg press, chest press, leg extension, and seated row. 1RM at baseline was assessed 2 times
separated by 1 week, and the best effort was recorded. An isokinetic dynamometer (CYBEX II,
Medway, MA) was used to measure strength of the knee extensors and flexors at 60_ per second;
data from the nondominant leg were used for analysis. Abdominal muscle endurance was assessed
using a modified curl‐up (crunch) test, counting the number of curl‐ups completed in 1 minute.
Physical performance was assessed with a timed 10‐repetition chair stand test using standard
29

procedures. Aerobic endurance was estimated by the 6‐minute walk test.
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Body Composition
Fasting weight was measured in a hospital gown on a digital scale to the nearest 0.1 lb. Whole‐body
composition was measured with dual‐energy x‐ray absorptiometry (DEXA) using a Hologic QDR‐
2000 scanner (Waltham, MA) in array mode and was read using accompanying manufacturer
software.

Main Outcomes
Midthigh CSMA was measured from images taken with computed tomography (CT) on a Sytec 4000
CT scanner (General Electric, Milwaukee, WI). The nondominant thigh was imaged in a scout film to
identify the full length of the femur. Using fixed bone landmarks at each end of the femur, the length
of the femur was measured and bisected. A 10‐mm cross‐sectional image was taken at the midpoint
of the femur using settings of 100 kV and 170 mA and was recorded digitally. Follow‐up films were
taken at the identical level of the same leg. The images were analyzed according to optical density
on a computer (Macintosh G3; Apple, Cupertino, CA) by a single investigator in a blinded fashion
using IMAGE software (version 1.38, National Institutes of Health, Bethesda, MD) modified for
2

quantification of cross‐sectional areas of fat, muscle, and bone to the nearest 0.1 cm .

Physical Functioning
Subjects were verbally administered the health‐related quality‐of‐life (HRQL) questionnaire used in
31

the HIV Costs and Services Utilization Study (HCSUS) by trained personnel. A 9‐item PF score was
coded and analyzed from the relevant items of the questionnaire.

Statistical Methods
Of the 50 enrolled subjects, 47 participants could be evaluated at 12 weeks and were included in
the intent‐to‐treat analysis. Calculations were conducted with SAS software (version 8; SAS
Systems, Cary, NC). Continuous baseline characteristics are described with medians and
interquartile ranges (IQRs), and binary characteristics are described with number and percentage.
The statistical significance of within‐group changes of the 3 treatment arms and of subgroups of
interest was assessed by a paired t test.
The statistical significance of differences in the pre‐and posttreatment changes within groups were
statistically evaluated by linear models with robust variance to allow for valid inference even when
32

the residuals are not normally distributed, comparing each of the intervention groups (OX or PRT)
with the NA group as the referent. Changes in the major outcomes (CSMA and PF) were tested with
and without the baseline value for the major outcome and with and without the inclusion of
outliers, defined as observations having outcome values falling outside the IQR. The results were
similar in all these cases, so the data from models without baseline values but including outlier

observations are presented. Interactions were tested by comparing models with the interaction
term included with corresponding models without the interaction term, using the likelihood ratio
(LR) test.

Cost and CostEffectiveness Analyses
Institutional costs for each intervention were calculated by multiplying quantities of each input
(personnel or supplies) times their unit costs in year 2000 prices at market value and summing the
products. The nutrition intervention cost included 12 counseling sessions, 2 food record collections,
and 12 weeks of canned supplements. OX costs included the nutrition intervention costs plus drug.
PRT costs included nutrition intervention costs with 3 months of gym fees and 36 personal training
sessions. Total costs also included calculation of expenses to the subject and society, namely,
transportation and time (opportunity) costs. Investigators developed an ECM, a protocol of these
interventions at an intensity level at which community resources or reimbursement would be more
33

feasible, as described by Cisler et al. Because of their lesser intensity, the interventions were
extended from 12 to 24 weeks to achieve theoretically comparable effectiveness to the study
protocol. The major differences in the ECM from the study interventions were monthly nutrition
counseling and weekly personal training sessions. OX was only proposed for 12 weeks for reasons
of safety.
To calculate cost‐effectiveness, the HRQL scores were translated into a single health state
classification or quality‐adjusted life‐year (QALY) measure for each client using methods of Brazier
et al.
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RESULTS
Baseline Subject Characteristics
Fifty subjects were enrolled in the study, and 47 completed the 12‐week trial, including 33 men and
14 women (Fig. 1). Other screened persons were not enrolled principally for reasons of not meeting
weight loss criteria, lack of interest in randomization, recent antiretroviral medication change, or
elevated liver function tests. No subjects were rejected because of an inability to tolerate milk,
steroids, or exercise. Eighteen subjects were randomly assigned to receive NA, 16 to receive OX
with nutrition, and 16 to receive PRTwith nutrition. Of the 2 men and 1 woman who did not
complete the study, 2 were in the NA arm and 1 was in the PRT arm.
The study population was ethnically and socioeconomically diverse. Seventy‐two percent of
subjects reported a household income of less than $20,000, 15% did not have secure housing, and
52% were nonwhite. Baseline characteristics of the subjects in the 3 arms are displayed in Table 1.
There was a slight imbalance (although not statistically significant, P = 0.23) of gender among the
arms, with women comprising one sixth of subjects in the NA arm and nearly half of the subjects in

the PRT arm. HAART use, laboratory values, and clinical status were similar among the arms. Forty‐
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two of the enrollees had a BMI ,20 kg/m . Although BMI was comparable among study arms, initial
fat‐free mass and muscle area were greatest in the NA arm, which included the greatest proportion
of men. Energy intake and self‐reported PF were similar among the arms.

Major Outcomes: CrossSectional Muscle Area
As shown in Table 2, CSMA did not change in the NA group, but it increased significantly in the OX
group and in the PRT group. The within‐group changes represented (mean 6 SE): 1% 6 1%, 7% 6
2.5%, and 5% 6 2% of the baseline value, respectively. There was a weak trend toward a difference
2

between the CSMA responses to OX and NA (difference = 5.0 cm , 95% confidence interval [CI]:
2

20.6, 10.5; P = 0.09) but not between responses to PRT and NA (difference = 3.3 cm , 95% CI: 21.9,
8.5; P = 0.26). Adjustment for gender and HAART did not materially alter these results. We also
tested the effect that individuals’ baseline values for CSMA may have had on the responses to
interventions. The CSMA response to OX seemed to be greatest among those in the lowest tertile of
baseline CSMA, whereas the CSMA response to PRT seemed to be similar among all tertiles. The
interactions of treatment with baseline CSMA value were not statistically significant (OX vs. NA: P =
0.19; PRT vs. NA: P = 0.81.)

Physical Functioning
Unadjusted self‐reported PF did not change significantly in the NA arm (6.9 6 5.1 points; P = 0.20),
and the change relative to the subjects’ baseline value was +18.7% 6 16.6%. There was also no
significant change in PF among the OX group (21.0 6 4.7 points or 23% 6 8.7%; P = 0.83). PF
improved significantly only in the PRT arm (10.4 6 3.8 points; P = 0.02), an increase relative to the
subjects’ baseline PF of +16% 6 6.3%. There were no overall statistically significant differences in
the crude PF responses between OX and NA (difference = 28.0 points, 95% CI: 221.8, +5.8; P = 0.24)
or between PRT and NA (difference = +3.4 points, 95% CI: 29.2, 16.1; P = 0.58). Adjustment for
gender and HAART use did not substantially change these findings.
Because more subjects than anticipated started with high PF values, we also considered the effect of
baseline PF value on response to treatment. The term for interaction between baseline PF and the
PRT intervention was statistically significant (OX vs. NA: P = 0.55; PRT vs. NA: P = 0.003). Including
interaction terms in the models revealed a net treatment effect of significantly greater
improvement with PRT than NA (P , 0.001) and greater improvement with NA than OX (P = 0.005).
The modeled responses within each tertile of baseline PF are shown in Figure 2. Changes were
small among persons with initially high PF and were greatest among those in the lowest tertile of
initial PF. Within each tertile, however, PRT seemed to induce the greatest increases in PF and OX
seemed to be least beneficial. In post hoc testing, there was a trend toward greater improvement in
PF with PRT than with OX (P = 0.08) and a statistically significant greater improvement in PF with
PRT than with OX after adjustment for the baseline PF value (P = 0.01).

Other Nutrition Outcomes
Table 2 also presents unadjusted within‐group changes in minor outcomes. Total energy intake
increased by 36% of baseline intake among all subjects; the increases in energy intake were
statistically significant among subjects in the NA and PRT groups but not in the OX group. Increases
in energy intake exceeded the 480 kcal provided by oral supplements by a modest amount in the
NA group and by a large amount in the PRT group but not in the OX group. Protein intake increased
significantly in all 3 groups, and these increases exceeded the
30 g/d provided by oral supplements. Models that included interactions for baseline values
demonstrated a significantly greater improvement with NA than with OX and with PRT than with
OX in energy and protein intake. There was no evidence of any increase in gastrointestinal
symptoms that could have interfered with intake in the OX group. Together, the 47 subjects
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achieved a modest but significant average increase in BMI (0.39 kg/m ; P = 0.01) and fat‐free mass
(1.27 kg; P , 0.001). There were no significant changes in BMI within any treatment arm, however.
In the NA and OX arms, fat‐free mass increased modestly but significantly (P = 0.04), and there was
a trend toward an increase (P = 0.06) in the PRT arm (NA: 0.90 kg 6 1.62; OX: 1.72 kg 6 3.00; PRT:
1.17 kg 6 2.24).

Strength, Power, and Performance Testing
Strength and power were evaluated with 4 different strength machine exercises, modified
abdominal curl‐ups, and two CYBEX II measures. There was a small but statistically significant
change only on the curl‐up test in the NA arm, and there were modest increases in 1 of the 1RMs
and the curl‐ups in the OX arm. Improvements on all tests were far exceeded by those in the PRT
arm, however, including statistically significant increases in all 4 1RMs, both CYBEX II measures,
and the modified curl‐ups. There were significant improvements in all groups in the 6‐minute walk
and repeated chair stand test.

Adherence to the Protocol
Subjects in all arms demonstrated high levels of adherence to the nutrition and pharmaceutic
protocols. They reported drinking almost all of the prescribed liquid supplements (NA: 94%, OX:
89%, PRT: 91%) and taking the study drug on 92% of the days in the trial (NA: 94%, OX: 88%).
Participants in the nonexercise arms attended 93% (NA) and 86% (OX) of their weekly nutrition
and monitoring sessions in person. PRT subjects attended an average of 72% of the 36 possible
training visits.

Adverse Events
Gastrointestinal symptoms were common during the course of the trial, but there was no evidence
of worsening by any intervention. Three people developed opportunistic infections during the
study, and 2 more were diagnosed with such conditions shortly after completion of the trial. There
were no deaths or serious or unexpected adverse reactions to the study interventions. Serious liver
function elevation developed in 2 study subjects and resulted in unblinding of study drug. One had
been assigned to OX and had hepatitis C with unrecognized ongoing alcohol intake; after
discontinuation of OX, her laboratory values quickly reverted to baseline. The other subject had
hepatitis attributable to efavirenz and had been taking placebo (NA) for the study. Another woman
receiving OX was diagnosed with osteonecrosis of the hip that radiographically antedated her
enrollment in the study. There were no reports of hirsuitism, deepening voice, sexual dysfunction,
menstrual change (among women), or gynecomastia (among men).

Cost and CostEffectiveness
The calculated institutional cost of OX with nutrition ($3772) was greater than the cost of PRT with
nutrition ($1636) or NA ($766) (Table 3). Expectedly, the total costs were higher than institutional
costs alone, and the ECM costs were lower than the study costs; however, the interventions
retained the same order of costliness. Each of the ECM totals included the following costs for
nutrition intervention: $163 for 12 weeks of canned nutrition supplements, $290 for nutrition
counseling, $34 for food records, and $109 for the client’s time and travel. Although no individual
arm demonstrated a large or significant change in QALYs, the increase was greatest in the PRT arm,
resulting in the most favorable cost‐effectiveness (lowest cost/QALY). Despite including a range of
possible costs, the cost‐effectiveness estimates did not overlap. Final calculations were
substantially least cost‐effective for OX.

DISCUSSION
This is the first study to directly compare nutrition therapy alone with 2 investigational strategies
for wasting and the first to test OX for these outcomes. The results demonstrate that 2 different
interventions supported with nutrition, OX and PRT, had comparable effects on body composition
in AIDS wasting. In contrast to OX, however, training had a stronger effect on protein and caloric
intake as well as strength and a stronger effect on PF, after consideration of baseline functioning,
than either of the other 2 interventions. One explanation for the additional PF benefits of the
exercise intervention may be that although both groups gained muscle, the quality of the muscle
produced may differ between the treatments. This possibility is supported by the absence of
strength increase accompanying the muscle mass increase seen with OX. Dietary intervention alone
successfully achieved increases in calorie and protein intake (more so than OX) and lean body mass,
although the benefits did not translate into measurably increased muscle mass or quality of life. The

finding that intensive nutrition therapy alone is effective in increasing dietary intake and lean mass
is important, given the safety and low cost of this approach.
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Although hypogonadal men with HIV infection should clearly be treated with testosterone, the
recommended course of treatment of women and eugonadal men with wasting is still uncertain.
Although additional testosterone seems to be of benefit, many patients and providers would prefer
an oral androgen if it were safe and effective. The lack of a significant difference between the
changes in muscle with OX and nutrition and the stronger benefits of nutrition and exercise on PF
do not support the overall benefit of the drug, however. Although the subjects in our study did not
experience any side effects, given our results and the potential toxicity of OX, it is difficult to justify
the wide use of this agent for HIV wasting.
We cannot exclude the possibility that some of the prior weight loss experienced by our subjects
represented lipoatrophy rather than wasting. Most of our participants had low BMIs, however, and
had struggled with weight loss and nausea, anorexia, or diarrhea for years, often since long before
beginning HAART. We attempted to verify that weight loss included substantial loss of fat‐free
mass, which was feasible in subjects who had undergone multiple DXA scans for the Nutrition for
Healthy Living (NFHL) cohort study at Tufts University. Data analysis shows that the average fat‐
free mass of this study’s participants was substantially lower than the average fat‐free mass of 284
unselected NFHL subjects with DXA scans in 1998 through 2001 (men: 52.7 kg 6 6.5 vs. 55.8 kg 6
7.0; women: 37.6 kg 6 4.2 vs. 40.8 kg 6 5.5). This suggests that we successfully selected participants
with true wasting and loss of lean body mass, even if they had also experienced fat atrophy.
Our findings differ from others in that earlier studies demonstrated greater success in increasing
weight than we did here with OX or exercise. There are several possible explanations for this
difference. First, exogenous androgen suppresses endogenous testosterone, theoretically limiting
its anabolic effect. Strawford et avoided this potential problem by administering both testosterone
and OX, although this is not how OX is used clinically. Increases in muscle mass in this study suggest
that the anabolic effect of OX overcame testosterone suppression. Moreover, some of the men in
this study were receiving replacement testosterone and could not have had gonadal suppression. It
is surprising that OX with nutrition had less effect on dietary intake and quality of life than did
nutrition intervention alone. Possible reasons for this are not known. Although OX still induced a
net anabolic effect, perhaps the suppression of endogenous testosterone resulted in decreased well‐
being through mechanisms that are not understood. Lower than anticipated attendance of exercise
sessions could also explain some lack of improvement in weight and lean body mass; however, the
strength effects of our training were considerable. Overall, there was still a statistically significant
increase in weight among all subjects during the course of the study.
12

Only 1 other study included separate arms with androgens and exercise alone. In that report,
weight, lean body mass, and muscle area seemed to increase more with testosterone than with
exercise, although direct comparisons were not reported. The subjects in that trial did not incur
increases in strength, however, suggesting that their training was ineffective. Numerous other
studies have demonstrated the benefits of exercise; however, effective exercise programs tailored

for the needs of the wasted HIV‐seropositive population are not provided as standard medical care
and are typically not covered by medical insurance.
Wasting persists as a major cause of morbidity and mortality in parts of the world without access to
8

antiretroviral agents. In these places, cost and cost‐effectiveness are critical. In the first analysis of
its kind, these results show the cost of delivering these interventions to be moderate and the cost‐
effectiveness to be borderline. Although it is not possible from this study to know the separate
contributions to the effectiveness of dietary supplements and dietary counseling, the costs of the
nutrition intervention were relatively low, including only 27% for the canned supplements
themselves. The most cost‐effective treatment was PRT with nutrition intervention, particularly
from an institutional perspective, which should encourage the interest of third‐party payers.
Because the major cost of PRT was the cost of trainers and the opportunity costs of patients, it
would be substantially less expensive in low‐income countries. OX was the least cost‐effective of the
interventions, even compared with NA, because it included similar or somewhat greater costs for
less of an increase in quality of life. This was true even at a level of intervention reasonably
24–27

these
delivered at a community level. Still, compared with other data in the AIDS literature,
costs are approximately 2 to 3 times higher than the cost per QALY gained for providing HAART.
Because provision of food is considered standard of care, because this was an effectiveness trial,
and because the cost and availability of food are so variable worldwide, the cost of food was not
included in our cost analyses. Nonetheless, securing adequate food and/or its cost must be a major
focus of providers treating AIDS wasting in resource‐poor settings.
This study shows the superiority of exercise over OX in improving PF when there is room for
improvement and a dramatic effect on strength, lean body mass, and dietary intake, with a low risk
of adverse effects at a lower cost and greater cost‐effectiveness. These results should encourage
providers, patients, and third‐party payers regarding its benefit as a medical therapy. It also
confirms the ability of dietary counseling with supplementation to improve nutrition, increasing
caloric and protein intake rather than just displacing other sources of energy, and to improve lean
body mass.
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Figures
Figure 1: Enrollment in the AllinONE trial

79 persons screened in-person
24 ineligible
5 chose not to enroll
50 persons enrolled
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Figure 2: Modeled change in physical functioning (PF) on a 100point scale by
treatment group and baseline PF score.
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Estimates and SEs are based on models, including the effect of treatment, the effect of the initial PF
value, and the effect of their interaction. Baseline PF was grouped as lowest tertile (initial PF
between 27 and 73), middle tertile (initial PF between 77 and 89), and highest tertile (initial PF
greater than 94). *P < 0.05 for within‐group change. NA indicates nutrition alone arm; OX,
oxandrolone arm; PRT, progressive resistance training arm.

Tables
Table 1: Baseline Clinical Characteristics, and Nutrition and Physical

Functioning Values
NA (N - 18)

Female gender (n)
Age (y)

Taking any ART (n)
Taking HAART (n)
Hepatitis or other AIDS-defining

3 (17%)
43.6 (37.3, 48.6)
15 (83%)
13 (72%)

6 (35%)

ox
5
40.8
14
14
6

(N - 16)

(3 I %)
(36.2, 45.2)
(88%)
(88%)
(38%)

PRT (N - 16)

7
43.2
12
II
4

(44%)
(38.4, 45.9)
(75%)
(69%)
(27%)

2
3
276
3.2
2623
109.9
20.6
45.2
110.4
89
3

(13%)
(20%)
(169, 495)
(2.3, 4.4)
(1848, 366 I)
(75.3, 131.6)
(19.1, 21.8)
(35.4, 52. I)
(96.8, IJJ.4)
(69, 94)
(19%)

condition (n)

Has hepatitis B (n)
Has hepatitis C (n)

CD4 (cells/rom 3 )
HIV RNA (Iog,JmL)
Energy intake (kcal/d)
Protein intake (gld)
8MI (kglm')
FFM (kg)

Muscle area (cm 2)

PF'
Initial PF

=

100 (n)

2 (14%)
3(21%)
243 (198, 412)
3.2 (2.3, 3.9)
2705 (2296, 3594)
108.0 (83.0, 131.8)
20.8 (19.6, 22.8)
53.3 (47.2, 59.4)
122.3 (99.0,152.5)
86 (72, 100)
5 (28%)

N(%), median, and IQR are shown.
·Measured on l~tOO scale, with 100 representing best functioning.
ART indicates antirctroviral therapy; FFM, fat-free mass.

2 (14%)

3
287
3.2
2285
96.9
19.8
45.3
113.1
89
5

(30%)
(202, 601)
(2.3, 4.0)
(1605, 3262)
(60.6, 115.5)
(18.0, 21.8)
(42.8, 53.4)
(94.8, 135.4)
(72, 100)
(3 I %)

Table 2: WithinGroup changes and BetweenGroup Comparisons of Major and

Minor Outcomes; Mean, Standard Deviation, and Probability Value of Change
in outcome

ANA
Acm

Muscle area (COIl)
PF,
8MI (kg/OIl)
FFM (kg)
Energy intake (kealfd)
Energy intake (kcal!kg/d)
Protein intake (gfd)
Protein intake (glkg/d)
Leg press (psi)
Chest press (psi)
Kncc extension (psi)
Scated row (psi)
CYBEX flexion (N-m)
CYBEX extension (N-m)
Curl-ups (reps)
Six-minute walk (yd)
Chair stands (s)

2.0
6.9
0.43
0.90
542
8.0
38.6
0.60
34
-3.3
0.79
3.2
-0.83
-1.08
3.0
277
-2.4

(5.3)
(20.5)
(0.90)
(1.62)·
(974)(14.3)(33.5)t
(0.53)t
(158)
(11.4)
(8.5)
(13.4)
(15.3)
(27.2)
(4.7)+
(245)(2.6)t

AOX
Mm

6.9
-1.0
0.35
1.72
403
7.0
32.3
0.57
48
3.8
2.6
6.4
3.36
-0.29
5.6
242
-2.9

(10.0)'"
(18.8)
(1.25)
(3.00)·
(1078)
(19.6)
(36.0)t
(0.66)t
(108)
(9.0)
(7.8)
(9.2)(13.41)
(19.6)
(7.4)(268)·
(2.5)t

.1.0X
Versus .1.NA
P = 0.09
P = 0.20
P = 0.84

P=0.31
P = 0.68
p = 0.86
P - 0.59
P = 0.87
P = 0.78
P= 0.12
P = 0.62
P = 0.50
P = 0.43
P = 0.93
P = 0.35
p,., 0.74
P = 0.64

60X Venus 6NA
(With Baseline
Interaetion)
P = 0.24
p,. 0.005

P = 0.62
P = 0.55
P < O.OOI§
P< 0.001§
P < 0.001§
P < O.OOI§
P = 0.57
p .. 0.96
p= 0.10
P = 0.70
p .. 0.08
p= 0.003
p= 0.51
P= 0.03
p= 0.14

Statistically significant between-group changes are shown in bold.
• p < 0.05: tP < 0.01.
*Mcasured on 1-100 scale. with 100 representing best functioning.
§Statislically significant (P < 0.05) interaction between the baseline value and the response to treatment
FFM indicates fat-free mass; N-m. N~'wton-mcteN; reps. repetitions.

.1.PRT
Arm

5.3
10.4
0.39
1.17
724
13.3
40.8
0.73
158
22.0
11.0
16.6
9.07
12.6
83
211
- 3.7

(9.0)·
(14.7)+
(0.94)
(2.24)
(844)t
(14.4)t
(30.7)t
(0.54)t
(132)t
(16.3)t
(11.6)t
(16.5)t
(13.7)+
(21.4)·
(9.0)1
(l88)t
(3.0)t

6PRT
Versus
ANA
P = 0.26

P = 0.59
P = 0.93
P = 0.75
P = 0.59
P = 0.35
P - 0.85
P = 0.54
P = 0.013
P < 0.001
P= 0.15
P = 0.007
P = 0.06
P= 0.11
P = 0.06
P-0.51
P=0.21

6PRT Venus
ANA (With Baseline
loteraetion)
P=
P<
P=
P=
p <
P=
Pp",

P
P
P
P
P
P
P
p
P

=
=

=
=
=
=
..
=

0.63
0.001§
0.79
0.17
0.001
0.04
0.005
0.07
0.35
0.005
0.76
0.02§
0.32
0.03
0.94
0.004§
0.007§

Table 3: Comparison of Institutional Costs per Subject

NA
OX versus NA

PRT versus NA

Institutional Study Cost

Total Study Cost

TOlal rCM Cost

S766.34
$3772.16
$1636.00

5983.36
$3772.16
S3189.38

5595.75
$3384.55
$2987.38

Change in QALYs

0.001 (P = 0.82)
0.022 (P- 0.61)
0.045 (P = 0.20)

rCM Cost/QALY (Range)
S45.243 (545.243-S64.335)
$146.709 ($146.709-$63.163)
S30,708 ($21.1 52-S355 1)

